Medical records for an aplastic anemia referral: making the evidence usable

The most useful referral file shows how the evidence fits together over time. A blood count obtained after transfusion, a marrow biopsy before treatment, and today's prescription describe different parts of the story. If those dates and circumstances are missing, even a large collection of reports can leave the specialist unable to judge what happened. Your role is to preserve the facts and their context. You do not need to reinterpret the diagnosis yourself.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

Begin with the first known abnormal counts, symptoms at presentation, important admissions, and the question you want the new team to address. Mark an approximate date as approximate. If an old record describes longstanding anemia but you remember symptoms beginning recently, include both accounts and identify where they came from. Resolving that difference may be clinically useful; replacing one account with the other conceals it.
A chromosome report should include the complete result and its technical limitations. Failure to obtain enough cells is not proof that the chromosome study was normal. Likewise, a sequencing report needs its test scope, method, sample type, detection limits, and interpretation. A variant of uncertain significance is not equivalent to a confirmed cause of inherited disease. Peffault de Latour et al.: Acquired Bone Marrow Failure, EBMT Handbook 2024 Diaz-de-Heredia et al.: Hereditary Bone Marrow Failure Syndromes, EBMT Handbook 2024
For an aplastic anemia review in China, obtain the requirements from the hematology or pathology service that will actually evaluate the case. Confirm whether electronic reports are sufficient for the initial opinion, whether translation is required, and how any loaned slides or blocks should reach the reviewing laboratory. Keep a record of material sent and its return arrangements. If you submit only a translated summary, identify where the original report and tissue remain so that an initial records discussion is not mistaken for a completed pathology review.

Quick answer

Full guide

Build a short timeline with links to the original evidence

Begin with the first known abnormal counts, symptoms at presentation, important admissions, and the question you want the new team to address. Mark an approximate date as approximate. If an old record describes longstanding anemia but you remember symptoms beginning recently, include both accounts and identify where they came from. Resolving that difference may be clinically useful; replacing one account with the other conceals it.

Add the dates of marrow examinations, treatment starts, major infections, interruptions, the best documented response, and any later deterioration. The timeline should point to the relevant reports rather than reproduce every laboratory value. Assessment of acquired aplastic anemia requires multiple kinds of evidence, and the specialist needs to see which information supported each earlier decision. BSH 2024 adult aplastic anaemia guideline ASH 2026 aplastic anemia guidelines

Use consistent file names that include the date, type of test, and institution. Avoid repeatedly naming different documents “latest results.” Keep identifying details, specimen dates, reference intervals, units, and page numbers in the scan. A cropped image of an abnormal result may omit the information needed to establish whose sample it was or whether a qualification appeared on the next page.

Show count trends together with transfusion dates

Useful blood count records include hemoglobin, platelets, differential white counts, absolute neutrophils, and absolute reticulocytes where available. A total white count or a reticulocyte percentage alone may not answer the specialist's question. Preserve original units when laboratories use different conventions. You can prepare a simple trend table for convenience, but attach the original reports so any conversion can be checked. Classification of severity also requires marrow findings and the relevant diagnostic context. Peffault de Latour et al.: Acquired Bone Marrow Failure, EBMT Handbook 2024

Place red cell and platelet transfusions alongside the counts, along with medicines that may have affected them. A good value shortly after a transfusion cannot be interpreted in the same way as a sustained value without support. Include periods when the patient still needed repeated transfusions despite apparently improved results. Selecting only the best laboratory sheet can obscure whether treatment produced a durable response.

Obtain records from emergency departments and other hospitals that provided blood products. The transfusion history should identify dates, components, significant reactions, known antibodies, and any evaluation for poor platelet increments. The receiving blood bank may need more than a note saying that a transfusion occurred. Record any instructions for leukoreduced or irradiated components accurately so that the new service can review them. Schrezenmeier et al.: Transfusion Support, EBMT Handbook 2024

If the original reports are incomplete, write down the gaps explicitly. A remembered transfusion and a documented transfusion are both worth mentioning, but should not be presented as equally precise records. Families sometimes spend considerable time rebuilding a history; a clearly labeled incomplete history is safer than a confident spreadsheet containing guessed dates or quantities.

Obtain the full marrow reports and ask about review material

Marrow aspirate morphology and the biopsy do not provide identical information. Look for both reports, any immunohistochemistry, and the associated laboratory studies. Preserve qualifications about inadequate material, dilution, limited interpretation, or the need for correlation. Translating only a concluding phrase such as “consistent with aplastic anemia” can omit the very limitation that another specialist needs to review. BSH 2024 adult aplastic anaemia guideline

Before requesting slides or a tissue block, ask the receiving pathology service what it accepts. The original laboratory may have a formal process for lending, shipping, and returning material. Do not alter the specimen yourself or send the only original material through an unconfirmed route. Photographs may help with an initial discussion, but the reviewing pathologist decides whether they are sufficient for the purpose.

Label each marrow sample as before or after disease treatment and attach the contemporaneous blood count. Note a significant infection or other event at the time. If several examinations were performed, retain the earlier material rather than assuming that the most recent biopsy makes it obsolete. Comparing changes can be part of the clinical assessment.

Keep the technical context of genetic and PNH testing

A chromosome report should include the complete result and its technical limitations. Failure to obtain enough cells is not proof that the chromosome study was normal. Likewise, a sequencing report needs its test scope, method, sample type, detection limits, and interpretation. A variant of uncertain significance is not equivalent to a confirmed cause of inherited disease. Peffault de Latour et al.: Acquired Bone Marrow Failure, EBMT Handbook 2024 Diaz-de-Heredia et al.: Hereditary Bone Marrow Failure Syndromes, EBMT Handbook 2024

For PNH flow cytometry, preserve the assessed cell populations, reported clone sizes, and laboratory comments. Place the report near contemporaneous hemolysis investigations and notes about relevant symptoms or thrombosis. PNH clones can coexist with aplastic anemia; their clinical importance depends on more than a positive label. Sending only a screenshot that says “PNH detected” can hide important distinctions. BSH 2024 adult aplastic anaemia guideline

The family history should record known facts: unexplained low counts, unusually early cancers, lung fibrosis, or other features that prompted medical concern. Include existing evaluations rather than assigning a genetic diagnosis to relatives yourself. For disorders such as Fanconi anemia, the interpretation of testing can affect both treatment planning and assessment of a potential related donor. GeneReviews: Fanconi Anemia, January 2026 update

Do not combine a somatic marrow panel and an inherited disease evaluation into one unnamed “gene test.” They may answer different questions and use different samples. If you are unsure which was performed, keep the laboratory's full title and report. A specialist can then decide whether the question has been answered or further testing is appropriate.

Describe what was actually taken, including interruptions

For each treatment, record the generic name, preparation, start and stop dates, actual dose history, and the reason for changes. A photograph of a medicine box is helpful for identification but does not establish how it was used. For antithymocyte globulin, obtain the specific product information, infusion chart, premedication record, and documented reactions. An undifferentiated entry labeled “ATG” may leave clinically relevant uncertainty. FDA: ATGAM prescribing information

Cyclosporine records are easier to interpret when levels are paired with sampling dates, the preceding dose time, the dose being taken, and kidney results. If the timing is unknown, say so. Record missed doses, reductions, and supply gaps without embarrassment. These details help distinguish drug exposure from disease behavior and are not a test of a patient's character. Include nonprescription medicines and supplements in the same reconciliation. MedlinePlus: Cyclosporine

For eltrombopag, retain treatment dates, the actual administration routine, and liver monitoring. Identify whether a pause resulted from toxicity, supply, a planned clinical decision, or difficulty following the food and mineral instructions. These are different explanations for a period without therapy. The pharmacist can review the relevant products and meals; the referral record should make that review possible. MedlinePlus: Eltrombopag

Make a previous response verifiable. State whether transfusions stopped, which cell lines improved, how long the improvement lasted, and whether treatment was continuing. Long-term studies distinguish response, relapse, and clonal changes, and the patient's record should preserve those distinctions too. A later fall in counts should not automatically be labeled relapse before its cause has been assessed. Patel et al.: Long-term outcomes after immunosuppression and eltrombopag

Create a separate transplant handover when applicable

Someone who has undergone transplantation needs the transplant date, donor and compatibility information, stem cell source, conditioning, graft-versus-host disease prophylaxis, engraftment history, and chimerism results. Include important infections and any acute or chronic graft-versus-host disease, identifying the affected organs and the treatment course. Evaluation of low counts after transplantation follows a different pathway from evaluation before transplantation. Suárez-Lledó and Rovira: Short- and Long-Term Controls After HCT, EBMT Handbook 2024

Add central line details, viral surveillance, current preventive medicines, revaccination records, and organ assessments. If the transplant center specifies particular blood components or monitoring, obtain that instruction in writing. “Infection prevention medicine” is not an adequate medication entry: the new team needs its name, current use, and planned review or stopping conditions.

Patients with several specialists should include the latest relevant letters from each service. The purpose is to reveal active problems and responsibilities, rather than to add every historical consultation indiscriminately. A kidney, lung, or infection issue can affect a marrow treatment decision even when another department is managing it.

Submit records to the hospital in China and preserve uncertainty in translation

For an aplastic anemia review in China, obtain the requirements from the hematology or pathology service that will actually evaluate the case. Confirm whether electronic reports are sufficient for the initial opinion, whether translation is required, and how any loaned slides or blocks should reach the reviewing laboratory. Keep a record of material sent and its return arrangements. If you submit only a translated summary, identify where the original report and tissue remain so that an initial records discussion is not mistaken for a completed pathology review.

Keep numbers, units, generic medicine names, and qualifications intact during translation. “Suspected,” “cannot exclude,” and “uncertain significance” should remain uncertain statements. Pair translations with originals and flag disputed terminology for review. Expanding an abbreviation on first use can prevent confusion between clinicians trained in different systems.

Confirm the receiving institution's secure submission method and the patient's authorization before sharing records. A directory and key documents can guide the initial review; large image files or pathology material should follow the service's instructions. Keep a complete patient copy instead of allowing the only usable record to become scattered among messages and attachments.

For the consultation, bring the current medicine list, recent counts, and the main decisions you want discussed. Distinguish a test that was never performed from one that was performed but has not yet been retrieved. An honest inventory of missing information allows the specialist to decide what should be repeated. The goal is a record that makes both the evidence and the gaps easy to understand.